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Abstract
BACKGROUND: Aberrant DNA methylation has been recognized in human breast carcinogenesis as a common
molecular alteration associated with the loss of expression of a number of key regulatory genes. The present study
was undertaken to determine whether methylation and expression of p16 and FHIT genes would correlate with the
estrogen receptor (ER) and progesterone receptor (PR) status. METHODS: Methylation-specific polymerase chain
reaction, messenger RNA (mRNA) expression analysis, immunohistochemistry, and Western blot analysis were
performed to study the methylation of p16 and FHIT genes in 351 pairs of malignant/normal breast tissues. We
examined the expression of ER and PR in those specimens by immunohistochemistry. Mutations of p16 and FHIT
genes in tumors were detected by direct sequencing. RESULTS: The frequency of hypermethylation was 31.9%
and 36.8% in p16 and FHIT genes, respectively, and showed significant harmony in concordant hypermethylation
(P < .0001). In postmenopausal patients, methylation frequency in both genes is significantly higher in poorly and
moderately differentiated tumors. Loss of protein expression of p16 and FHIT in 77 and 74 tumors, respectively, is
associated with their methylation status in premenopausal women. CONCLUSION: We did not find any significant
differences in tumor-related gene methylation patterns relevant to both ER and PR status of breast tumors.
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Introduction
Breast cancer is the single most common cause of cancer-related mor-
tality in women worldwide, accounting for an annual prevalence of
more than 1 million new cases, representing nearly one fifth of all
malignancies among females [1]. The incidence of breast cancer is
increasing in many countries particularly in Asia, with more than
3% increase every year compared with just more than half a percent
in developed countries [2]. Breast cancer among younger women is
appearing as the leading cancer in India. These tumors are often es-
trogen receptor (ER)– and/or progesterone receptor (PR)–negative;
however, their mechanistic basis remains elusive [3]. Aberrant DNA
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methylation has been increasingly recognized as a frequent molecu-
lar alteration in breast cancers. Hypermethylation of the CpG islands
is associated with delayed replication, condensed chromatin, inhibi-
tion of transcription initiation, and silencing of genes [4]. Genes in-
volved in cell cycle regulation (p16 ), cell adhesion (CDH1), DNA
repair (BRCA1), and cell signaling pathway (ER, RARβ2) have been
reported to undergo hypermethylation [5,6]. The product of INK4A
locus, p16, encodes a cyclin-dependent kinase (CDK) inhibitor that
functions as a negative regulator of cyclin/CDK complexes. It binds
preferentially to CDK4/6 and prevents their association with D-type
cyclins, thus inhibiting pRB phosphorylation and progression
through the cell cycle [7,8]. It plays an important role in maintaining
normal cellular properties, preventing both centrosome dysfunction
and genomic instability [9]. Inactivation of p16INK4A is an early
event in carcinogenesis [7,8], and loss of p16/Rb activity occurs
through different mechanism such as deletion, mutation, and/or hy-
permethylation of p16INK4A [8]. Inactivation of p16 seems a crucial
event in the development of several tumors [10]. The relevance of
this defect in mammary carcinogenesis remains unclear. However,
homozygous deletions of this gene are seen in half of the breast can-
cer cell lines and neither homozygous deletions nor point mutations
are frequently observed in primary breast cancers, suggesting that
these alterations might have been acquired in the cultures [11,12].
There are suggestions that aberrant hypermethylation may be a use-
ful biomarker, with implications for breast cancer etiology, diagnosis,
and management. FHIT is also found frequently inactivated in many
tumor types, including those of breast, cervix, esophagus, digestive
tract, lung, and bladder [13–17].
Prognostic factors considered negative for survival such as ad-
vanced diagnosis stage (enlarged tumor size, node involvement, and
sometimes more distant metastasis), early onset disease (<50 years
age), ER and PR status, poor differentiation of tumors and obesity
might play an important role in the etiology of this disease. The
aim of the present study was to evaluate the association between the
major clinicopathologic features of breast cancer and methylation sta-
tus of p16 and FHIT genes among primary breast cancer cases. We
also tried to delineate more precisely the association of p16 and FHIT
methylation and their expression using Northern and Western blot
analyses along with immunohistochemistry profile among breast can-
cer patients from northern India.
Materials and Methods
Sample Size
A total of 379 breast tumor and adjacent normal tissue biopsies
not infiltrated by tumors as confirmed by a pathologist were collected
directly from patients attending the Institute Rotary Cancer Hospital,
All India Institute of Medical Sciences, New Delhi. The samples were
from breast tumors and corresponding adjacent normal-appearing
tissues (from tissues located at least 3 cm away from the site at which
the tumor was sampled). However, data from only 351 (299 ductal
and 52 lobular) breast tumor biopsies have been analyzed owing
to either insufficient quantity and/or quality of DNA and RNA of
the other 28 tumor and/or adjacent tissue specimens. Biopsies were
collected directly into sterile collection vials containing chilled PBS
(pH 7.2) and were stored in liquid nitrogen or −80°C until further
analysis. The tissue materials were used for DNA and RNA extrac-
tion. The present study was approved by the university and institu-
tional review boards. The histologic type and grade of the tumors
were classified according to the World Health Organization’s criteria.
Prior consent from the patients was also taken before starting the
study. All breast specimens including tumor and normal adjacent tis-
sue were reviewed by two experienced pathologists at the hospital.
Slides prepared from these were subject to immunoperoxidase staining
for ER (clone 6F11) and PR (clone 1A6) as per the manufacturer’s
(Novocastra Laboratories Ltd, Benton Lane, UK) recommendations.
Cancers were considered receptor-positive if more than 10% of malig-
nant cells showed nuclear staining. Cancers were classified as ER- and/
or PR-positive.
Methylation-Specific Polymerase Chain Reaction
Methylation status of the promoter regions of p16 and FHIT
genes was determined by methylation-specific polymerase chain re-
action (MSP) as described previously [18]. Primer sequences and an-
nealing temperatures for the MSP were as described previously in the
literature [18,19]. Each reaction mixture contained 1× polymerase
chain reaction (PCR) buffer, 1.5 mM MgCl2, 1.25 mM each of
the dNTPs, primers (300 ng each/reaction), 1.5 U of Taq poly-
merase, and bisulfite-modified DNA (50 ng). Reactions were hot-
started at 95°C and carried out for 35 cycles, and each cycle consisted
of 45 seconds at 95°C, 75 seconds at 65°C and 60°C for p16 and
at 69°C and 67°C for FHIT, respectively, for methylated and un-
methylated specific PCR and 60 seconds at 72°C, followed by 7 min-
utes of final extension at 72°C. Each PCR product (15 μl each) was
run on 2.5% agarose gel, stained with ethidium bromide, and visu-
alized under UV illumination. DNA from peripheral blood lympho-
cytes of a healthy individual was treated with SssI methyltransferase
(New England Biolabs, Inc, Ipswich, MA) was used as a positive con-
trol. To confirm the methylation status by bisulfite sequencing, a
subset of the patients who show unmethylation and methylation in
p16 and FHIT was chosen, and we found that these results match
with the results obtained by MSP (data not shown). Appropriate
controls were set up in each reaction. Representative examples are
shown in Figure 1A.
Mutation Analysis in p16 and FHIT Genes
p16 (exon 2) and FHIT (exon 5-8) gene mutations analysis was
performed by single-strand conformation polymorphism. Mutations
were detected by direct sequencing of relevant genomic DNA frag-
ments showing an aberrant profile in the single-strand conformation
polymorphism analysis.
RNA Extraction and Northern Blot
RNA was extracted from the breast tumor tissues using guanidium-
isothiocyante method was electrophoresed in 3-[N -morpholino]-
propanesulfonic acid gel to ascertain the quantities of extracted RNA.
From each sample, 1 μg of RNA was resolved on 1% agarose-4-
morpholinepropanesulfonicacid/formaldehyde gel, transferred to a
nylon membrane, and hybridized for 16 to 18 hours to a radiolabeled
FHIT or p16 complementary DNA probe. After 16 to 18 hours of
hybridization, the membrane was washed three times with a washing
solution (2× SSC, 0.1% SDS) for 15 minutes each at 65°C, and the
membrane was exposed to a Kodak X-Omat X-ray film (Carestream
Health, Inc, Rochester, NY) in x-ray cassette with intensifying screen
at −20°C for 24 hours, and the autoradiogram was developed. Rep-
resentative examples are shown in Figure 1B.
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Western Blot Analysis
Frozen tissue samples were homogenized in lysis buffer (20 mM
Tris-HCl at pH 7.5, 1 mM EDTA, 1 mM EGTA, 150 mM sodium
chloride, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate,
1 mg/ml leupeptin, 1 M phenylmethylsulfonyl fluoride), and protein
content was quantified. A total of 25 μg of protein was run on a 12%
sodium dodecyl sulfate (SDS)–polyacrylamide gel, transferred on to
nitrocellulose membranes, probed either with an antihuman p16
(1:500; BD Pharmingen, San Jose, CA) or FHIT (1:2000; Zymed
Laboratories, San Francisco, CA) and electrotransferred to a nitrocel-
lulose membrane. The membrane was incubated in a blocking buffer
(1 g/L Tween-20 with 50 g/L nonfat dry milk in Tris-buffered saline)
for 2 hours. The membrane strip was then incubated with FHIT
antibody overnight at 4°C. The expressions of p16 and FHIT protein
were detected using routine methods. The same blots were reprobed
with antiactin monoclonal antibodies to assure equal loading in each
lane. Representative examples are shown in Figure 1C .
Immunohistochemistry for p16 and FHIT
Deparaffinized tissue sections in citrate buffer were heated in micro-
wave for 15 minutes for antigen retrieval for p16 and FHIT genes.
Tissue sections were incubated with 3% H2O2 (15 minutes) to block
endogenous peroxidase with 10% normal horse serum in phosphate-
buffered saline (10 minutes). Primary antibodies against p16 and
FHIT (1:200 dilutions; Zymed Laboratories) were applied at room
temperature for 1 hour followed by binding to secondary antibody
and streptavidin horseradish peroxidase conjugate (20 minutes;
Dako, Carpinteria, CA). Normal colonic epithelial cells served as
internal positive controls with membrane staining. Cytoplasmic, nu-
clear, and membrane expressions were recorded separately as no ex-
pression, weak expression, or moderate/strong expression. Positivity
in each compartment (cytoplasm, nucleus, or membrane) was de-
fined as moderate/strong expression in that compartment. We cal-
culated activation score as the sum of nuclear score (+2 = positive
expression; +1 = weak expression; 0 = no expression), cytoplasmic
score (+2 = positive expression; +1 = weak expression; 0 = no expres-
sion), and membrane score (0 = positive membrane expression; +1 =
negative membrane expression). Appropriate positive and negative
controls were included in each experiment. Coded slides were scored
by one of the investigators (M.R.). At least 25% slides were checked
independently by other investigator(s) to rule out any bias. Repre-
sentative examples are shown in Figure 2 (A to F ).
Statistical Analysis
The χ 2 test was used to compare the distributions of the methyl-
ation status of individual genes and various features of breast cancer.
Unconditional logistic regression was used to assess odds ratios (ORs)
and 95% confidence intervals (CIs). All models were adjusted for age
at diagnosis, smoking, and education level. Potential confounding ef-
fects from other demographic factors and known breast cancer risk
factors, including age at menarche, age at menopause, parity, family
history of breast cancer, and body mass index, were also examined,
and no appreciable confounding was observed. All statistical tests
were based on two-sided probability. Statistical analyses were con-
ducted using SPSS Version 14.0 (SAS Institute, Cary, NC). Differ-
ences were considered statistically significant for P < .05.
Results
Primary clinical and pathologic characteristics of patients are shown
in Table 1. The frequency of hypermethylation was 31.9% and
36.8% for p16 and FHIT genes, respectively. Promoter region CpG
hypermethylation for any of these two genes was identified in 165
(47%) of 351 primary tumors. Seventy-six patients (21.6%) showed
hypermethylation for both genes (Table 2). Methylation profile of
these genes in normal adjacent tissues from the same patient was
also investigated, and we found very low methylation (1.4% and
1.6% of p16 and FHIT, respectively). Patients who showed meth-
ylation in either of these genes in normal tissue were found to be
methylated in tumor tissue as well. Among premenopausal women,
hypermethylation of both p16 and FHIT is significantly higher (OR =
1.71, 95% CI = 1.1-2.89, P = .039 and OR = 1.79, 95% CI = 1.2-
2.98, P = .025, respectively, for p16 and FHIT; Table 3) compared
with postmenopausal women. The relationship between individual
gene hypermethylation status with clinical and pathologic features
of breast cancer was evaluated stratifying by the menopausal status
(Table 4). Associations varied somewhat by menopausal status. For
premenopausal women, there was a significant association of p16
hypermethylation with ER status, whereas FHIT hypermethylation
status is significantly associated with TNM stage (Table 4). In post-
menopausal women, p16 hypermethylation is significantly associated
with histologic grade of the tumors, whereas FHITmethylation is
associated with age at diagnosis of the disease. In postmenopausal
women, methylation of both p16 and FHIT is significantly associated
with the differentiation of the tumors (OR = 3.18, 95% CI = 1.53-
9.61 and OR = 3.09, 95% CI = 1.27-7.96 for p16; OR = 2.51,
95% CI = 1.15-6.65 and OR = 2.86, 95% CI = 1.07-7.42 for
FHIT gene, respectively; Table 5). Methylation of FHIT gene in pre-
menopausal women is significantly associated with stage of tumors
Figure 1. (A) Methylation status of p16 and FHIT genes in normal
and tumor tissues from the same patient. (B) Northern blot analy-
sis showing mRNA expression profile of FHIT, p16, and β-actin in
different breast cancer patients. Lane marked N: normal breast
tissue, T: tumor tissue. (C) Western blot analysis in the same pa-
tients analyzed for Northern blot.
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(TNM;OR = 6.1, 95%CI = 1.68-21.52 andOR = 6.2, 95%CI = 1.7-
22.6; Table 5). No associations were observed for tumors exhibiting
negativity with ER and PR status (Table 5). We found concordant
hypermethylation (P < .001) in p16 and FHIT genes.
The MSP approach only allows the samples to be scored either
positive or negative for the presence of methylated 5′CpG island se-
quences. Therefore, no discrimination can be made in the degree of
5′CpG island methylation in any of these samples. Hence, to estab-
lish a relationship between positive MSP results with reduced p16
and FHITmRNA expressions, we compared p16 and FHIT expres-
sion levels between the samples displaying methylated and unmeth-
ylated p16 and FHIT genes, for those patients where both expression
and MSP data were available. Methylation of p16 gene is significantly
associated with low/loss of expression (OR = 1.87, 95% CI = 1.1-
3.25; Table 6). Similarly, low/loss of FHIT expression is significantly
correlated with methylation status (OR = 2.59, 95% CI = 1.54-4.38;
Table 6). We hypothesized that mutations in p16 and FHIT genes
can also lead to reduced/low expression irrespective of their methyla-
tion status. However, we did not find any mutations in p16 and FHIT
genes that could result in the loss of their expression in tumors.
Discussion
We evaluated the association between gene hypermethylation and ex-
pression of p16 and FHIT genes with various clinicopathologic char-
acteristics in primary breast tumors. The aim of the study was to
further understand the role of the previously mentioned genes in the
natural history of breast carcinogenesis as well as a molecular predictor
of disease progression. Promoter hypermethylation for at least one gene
was found in 47% of the breast tumors. Methylation frequencies of
various genes associated with breast cancer varied in different popula-
tions. In this study, we found that methylation frequencies for p16 and
FHIT genes in our cohort were slightly different to those reported pre-
viously [20–22]. This variation could be attributed to the sample tissue
with a high proportion of cancerous cells or to ethnic differences.
The most common inactivated tumor suppressor gene in human
cancer (p16) is a CDK inhibitor that form complexes with CDK4,
CDK6, and D-type cyclins to arrest cell cycle’s progression from G1
to S phase [23]. Hypermethylation of p16 gene is an early and critical
step in breast cancer development [24,25]. In the present study, we
found higher methylation frequency for p16 and FHIT genes if pa-
tients show positivity for both ER and PR status compared with ER-
negative especially among premenopausal women. However, we did
not observe any associations of p16 hypermethylation with other
clinicopathologic features of breast cancer. The strongest associa-
tion observed in this study of specific gene methylation in p16 and
FHIT genes was found in postmenopausal women with poorly
differentiated tumors. This finding is important because it links
DNA hypermethylation with the histologic appearance of breast can-
cers. Previous studies have also reported associations between CpG
island methylation and poor histologic differentiation of breast tu-
mors [20,21,26,27]. It is possible that p16 might play an important
role in the initiation and progression of certain premalignant lesions
and carcinoma that can act as a crucial event in cell transformation.
Loss of p16 protein expression resulting from its methylation played
an important role in the evolution of this event. We found reduced
FHIT expression in a subset of BRCA2 linked breast cancer (data not
shown here). However, FHIT expression is either absent or signifi-
cantly reduced in some patients (22%), and this loss of the expres-
sion is within the range reported elsewhere [14,28]. A significant
Figure 2. Immunohistochemical detection of p16 and FHIT protein in breast cancer patients. (A–C) Progressive loss of p16 in different
patients: (A) normal epithelium shows consistent and strong staining for p16, (B) low or reduced p16 expression, and (C) no expression
of p16. (D–E) Progressive loss of FHIT in different patients: (D) normal epithelium of breast tissue stains consistently and strongly for
FHIT protein; (E) low or reduced expression of FHIT gene; and (F) no expression of FHIT protein in breast cancer patients.
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proportion of breast cancer patients (78%) showing normal FHIT
expression without any apparent methylation further indicate that
routes independent of this gene may be involved in the pathogenesis
of this disease, and these findings are in agreement with a previously
published report [14]. We found a similar incidence of tumors, show-
ing loss of expression of p16 genes that is comparable with previously
published reports [29–31].
Methylation in breast cancer has long been linked to the hormone
regulation, but this correlation is not intelligible yet. DNA methyl-
ation profiles in breast, endometrial, ovarian, and proximal colon
cancers provide contradictory evidence for global hormone-specific
DNA methylation signatures [32,33]. However, in this study, we
did not find hormone biology to play any significant role in the
methylation status of these genes. In postmenopausal women, FHIT
gene hypermethylation is more frequent among ER- and PR-negative
patients. However, p16 gene is less methylated in tumors that are
negative for PR status both in premenopausal and postmenopausal
women. In a recently published report, methylation of RASSF1A,
CCND2, GSTP1, Twist, and APC is correlated well with ER status
among breast cancer patients [34].
Major progress in controlling mortality and morbidity from cancer
requires better understanding of molecular mechanisms underlying
disease initiation. Analysis of early aberrant events is complex because
by the time the tumor is detected, the cancer progenitor cells may have
already undergone multiple changes both at genetic and epigenetic lev-
els. In current clinical practice, both ER and PR status are very impor-
tant to help determine patients who would benefit most from hormone
Table 1. Clinicopathologic Parameters in Breast Cancer Patients.
Clinicopathologic Variables Patients Percentage
Age (years)
<50 156/351 44.5
>50 195/351 55.5
Nodal association
Positive 231/351 65.8
Negative 120/351 34.2
Histologic grading
PD 156/351 44.4
MD 138/351 39.3
WD 57/351 16.4
Histologic status
Infiltrating ductal carcinoma 299/351 85.4
Infiltrating lobular carcinoma 52/351 14.8
ER
Positive 293/351 83.5
Negative 58/351 16.5
PR
Positive 271/351 77.2
Negative 80/351 22.8
Methylation
p16 methylation 112/351 31.9
FHITmethylation 129/351 36.8
p16 gene expression (mRNA)
Normal 284/351 80.9
Low 45/351 12.8
Nil 22/351 6.3
FHIT gene expression (mRNA)
Normal 277/351 78.9
Low 43/351 12.3
Nil 31/351 8.8
p16 gene expression (immunohistochemistry)
Normal 284/351 80.9
Low 45/351 12.8
Nil 22/351 6.3
FHIT gene expression (immunohistochemistry)
Normal 277/351 78.9
Low 43/351 12.3
Nil 31/351 8.8
TNM clinical stage
I 43/351 12.3
II 138/351 39.3
III and IV 170/351 48.4
Premenopausal status
p16 methylation 46/117 39.3
FHIT methylation 53/117 45.3
Postmenopausal status
p16 methylation 66/234 28.2
FHIT methylation 76/234 32.5
Table 2. Correlation between p16 and FHIT Methylation in Breast Cancer Patients.
Promoters FHIT Methylated FHIT Unmethylated Total OR (95% CI)
p16 methylated 76 36 112 7.68* (4.5-12.6)
p16 unmethylated 53 186 239 1.0 (reference)
Total 129 222 351
Odds ratios and 95% CI were estimated with unconditional logistic model adjusted for various
confounding factors such as age at the time of diagnosis and smoking habits; *P = .05.
Table 3. Association of Hypermethylation in p16 and FHIT Genes in Association with Pre-
menopausal and Postmenopausal Status in Breast Cancer Patients.
Promoters Premenopausal Postmenopausal P OR (95% CI)
p16 unmethylated 71 168 1.0 (reference)
p16 methylated 46 66 .039 1.71* (1.1-2.89)
FHIT unmethylated 64 158 1.0 (reference)
FHIT methylated 53 76 .025 1.79* (1.2-2.98)
Odds ratios and 95% CI were estimated with unconditional logistic model adjusted for various
confounding factors such as age at the time of diagnosis and smoking habits; *P < .05.
Table 4. Association of p16 and FHIT Hypermethylation with Selected Clinicopathologic Factors.
Clinicopathological Factors Premenopausal Women Postmenopausal Women
p16 FHIT p16 FHIT
M UM M UM M UM M UM
Age at diagnosis (years)
<50 41 56 42 49 2 11 2 11
50-59 5 15 11 15 58 137 59 136
≥59 — — — — 6 20 14 12
P .21 .82 .44 .02*
Histologic grade
Well 2 10 3 9 6 39 8 37
Moderate 19 29 24 24 29 61 31 59
Poor 25 32 26 31 31 68 37 62
P .21 .29 .047* .058
TNM stage
I 5 15 3 17 3 20 4 19
II 22 30 27 25 28 58 32 54
III and IV 19 26 23 22 35 90 40 85
P .35 .01* .18 .19
ER status
Positive 43 53 47 49 57 140 63 134
Negative 3 18 6 15 9 28 13 24
P .009* .09 .58 .71
PR status
Positive 39 50 41 48 54 128 57 125
Negative 7 21 12 16 12 40 19 33
P .08 .77 .35 .49
ER/PR
Both positive 19 33 23 29 26 68 28 66
Either positive 12 28 16 24 24 70 31 63
Both negative 15 10 14 11 16 30 17 29
P .047* .44 .51 .69
*Significant at *P < .05.
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therapy. Depending on the hormone receptor and menopausal status of
the patient, different treatment regimens can be used. A recent retro-
spective clinical analysis of patients established that both ER-positive/
PR-negative and ER-positive/PR-positive breast cancers are clinically
and biologically distinct tumor subgroups. The presence of both PR
and ER in breast cancer specimens suggests a likelihood of positive re-
sponse to hormonal therapy, most probably because the presence of
PR indicates an intact and functional ER pathway. However, in the cur-
rent study, we found that tumors with both ER-negative–PR-positive
phenotype (10%) and an ER-positive–PR-negative phenotype (9%)
exist, and a previous category is another heterogenous group that has
been found to be biochemically distinct from ER-PR–positive tumors
[35]. When combined with the methylation status, these groups fur-
ther have the potential to respond differently to the various treatment
options currently available to patients. We observed that premeno-
pausal patients who were negative for both ER and PR showed p16
and FHITmethylation more frequently compared with postmeno-
pausal women. Therefore, a larger study is needed to confirm these
findings. Both ER and PR expressions can be downregulated in a num-
ber of ways including the structural loss of ER and PR gene loci and/or
hypermethylation in their promoter regions.
The strengths of the present study include its population-based
study design, similar ethnic background, and relatively large sample
size leading to relatively stable risk estimates. In summary, the present
study suggests that p16 and FHIT hypermethylation is associated
with histologic grade, although there is no indication that the hyper-
methylation of these genes is associated with ER and PR status.
However, further research is needed to assess the association of these
tumor characteristics with other breast cancer risk factors for better
understanding the etiology of this cancer type.
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Moderate 3.37 (0.65-17.25) 3.11 (0.85-10.16) 3.18* (1.53-9.61) 2.51* (1.15-5.65)
Poor 3.96 (0.82-18.79) 2.61 (0.92-9.72) 3.09* (1.27-7.96) 2.86* (1.07-7.42)
TNM stage
I 1.0 (reference) 1.0 (reference) 1.0 (reference) 1.0 (reference)
II 2.4 (1.1-2.9) 6.1* (1.68-21.52) 3.38 (0.97-11.36) 2.71 (1.21-8.2)
III and IV 2.3 (0.7-6.9) 6.2* (1.7-22.6) 2.43 (1.14-8.94) 2.35 (1.08-8.9)
ER status
Positive 1.0 (reference) 1.0 (reference) 1.0 (reference) 1.0 (reference)
Negative 0.22 (0.06-1.54) 0.59 (0.1-4.23) 0.81 (0.46-2.15) 1.25 (0.63-2.76)
PR status
Positive 1.0 (reference) 1.0 (reference) 1.0 (reference) 1.0 (reference)
Negative 0.49 (0.17-1.2) 0.92 (0.56-2.31) 0.82 (0.41-1.53) 1.36 (0.71-2.97)
ER/PR status
Both positive 1.0 (reference) 1.0 (reference) 1.0 (reference) 1.0 (reference)
Either positive 0.81 (0.34-2.68) 0.91 (0.36-2.07) 1.04 (0.55-1.39) 1.25 (0.73-2.75)
Either negative 2.71 (1.21-5.89) 1.68 (0.74-3.89) 1.51 (0.75-3.36) 1.43 (0.81-3.52)
Odds ratios and 95% CI were estimated with unconditional logistic model adjusted for various confounding factors such as age at the time of diagnosis and smoking habits.
*Significant at P < .05.
Table 6. Association between Methylation of p16 and FHIT and Their Expression Analyzed by
mRNA Analysis and Immunohistochemistry.
Gene Low/Nil Expression Normal Expression OR (95% CI)
p16 unmethylated 19 220 1.0 (reference)
p16 methylated 29 86 1.87* (1.1-3.25)
FHIT unmethylated 32 184 1.0 (reference)
FHITmethylated 42 93 2.59* (1.54-4.38)
*Significant at P < .05.
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